Shannon Wong, Medical Student, Do Patients with Different Subtypes of Myelodysplastic Syndromes (MDS) and Transfusional Iron Overload Have Different Degrees of Clinical Benefit (Reduction in Transfusion Requirements, AML-Free Survival, Overall Survival) from Iron Chelation Therapy?
Shannon Wong, Medical Student, Predictors of Hematologic Improvement in Lower Risk MDS Patients Receiving Iron Chelation Therapy.
Colleen Wong, Medical Student, Iron Overload in Patients with Myelodysplastic Syndrome: Relation to Infections.
Shannon Wong, Medical Student, Paroxysmal Nocturnal Hemoglobinuria (PNH) Screening in Patients with Myelodysplastic Syndrome (MDS) in Clinical Practice: Frequency and Indications.
James England, Medical Resident, Do Patients With Acute Myelogenous Leukemia and Transfusional Iron Overload (IOL) who are Receiving and Responding to Azacitidine Have Clinical Benefit from IOL Reduction with Phlebotomy or Iron Chelation Therapy?
James England, Medical Resident, Paroxysmal Nocturnal Hemoglobinuria (PNH) Screening in Patients with Unexplained Anemia: A Single Institution Experience.
Katie Zhu, Medical Student, Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada.